H.C. Wainwright lowered the firm’s price target on Summit Therapeutics (SMMT) to $44 from $45 and keeps a Buy rating on the shares following the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics Advances NSCLC Trials and Strengthens Financials
- Summit Therapeutics reports Q3 EPS (5c), consensus (7c)
- Summit Therapeutics Advances Ivonescimab for Lung Cancer
- SMMT Earnings this Week: How Will it Perform?
- Summit Therapeutics up after Fast Track designation, trial enrollment completion